

PCT INTERNATIONAL COOPERATION TREATY

PCT

NOTIFICATION OF ELECTION

(PCT Rule 61.2)

From the INTERNATIONAL BUREAU

To:

Commissioner
 US Department of Commerce
 United States Patent and Trademark
 Office, PCT
 2011 South Clark Place Room
 CP2/5C24
 Arlington, VA 22202
 ETATS-UNIS D'AMERIQUE
 in its capacity as elected Office

Date of mailing (day/month/year) 09 July 2001 (09.07.01)	
International application No. PCT/EP00/09708	Applicant's or agent's file reference N.80650 CMK
International filing date (day/month/year) 04 October 2000 (04.10.00)	Priority date (day/month/year) 05 October 1999 (05.10.99)
Applicant BOLOGNA, William, J. et al	

1. The designated Office is hereby notified of its election made:

☒ in the demand filed with the International Preliminary Examining Authority on:
 12 April 2001 (12.04.01)

☐ in a notice effecting later election filed with the International Bureau on:

2. The election ☒ was

☐ was not

made before the expiration of 19 months from the priority date or, where Rule 32 applies, within the time limit under Rule 32.2(b).

The International Bureau of WIPO
 34, chemin des Colombettes
 1211 Geneva 20, Switzerland

Facsimile No.: (41-22) 740.14.35

Authorized officer

Nestor Santesso

Telephone No.: (41-22) 338.83.38

PCT COOPERATION TREATY

PCT

NOTIFICATION RELATING TO PRIORITY CLAIM

(PCT Rules 26bis.1 and 26bis.2 and
Administrative Instructions, Sections 402 and 409)

From the INTERNATIONAL BUREAU

To:

KEEN, Celia, Mary
J.A. Kemp & Co.
14 South Square
Gray's Inn
London WC1R 5LX
ROYAUME-UNI

Date of mailing (day/month/year) 17 January 2001 (17.01.01)	IMPORTANT NOTIFICATION
Applicant's or agent's file reference N.80650 CMK	
International application No. PCT/EP00/09708	International filing date (day/month/year) 04 October 2000 (04.10.00)
Applicant COLUMBIA LABORATORIES (BERMUDA) LIMITED et al	

The applicant is hereby **notified** of the following in respect of the priority claim(s) made in the international application.

1. ☒ **Correction of priority claim.** In accordance with the applicant's notice received on: 20 December 2000 (20.12.00), the following priority claim has been corrected to read as follows:

US 25 September 2000 (25.09.00) 09/668,384

☐ even though the indication of the number of the earlier application is missing.

☐ even though the following indication in the priority claim is not the same as the corresponding indication appearing in the priority document:
2. ☐ **Addition of priority claim.** In accordance with the applicant's notice received on: , the following priority claim has been added:

☐ even though the indication of the number of the earlier application is missing.

☐ even though the following indication in the priority claim is not the same as the corresponding indication appearing in the priority document:
3. ☐ As a result of the correction and/or addition of (a) priority claim(s) under items 1 and/or 2, the (earliest) priority date is:
4. ☐ **Priority claim considered not to have been made.**

☐ The applicant failed to respond to the Invitation under Rule 26bis.2(a) (Form PCT/IB/316) within the prescribed time limit.

☐ The applicant's notice was received after the expiration of the prescribed time limit under Rule 26bis.1(a).

☐ The applicant's notice failed to correct the priority claim so as to comply with the requirements of Rule 4.10.

The applicant may, before the technical preparations for international publication have been completed and subject to the payment of a fee, request the International Bureau to publish, together with the international application, information concerning the priority claim. See Rule 26bis.2(c) and the PCT Applicant's Guide, Volume I, Annex B2(IB).
5. ☐ In case where **multiple priorities** have been claimed, the above item(s) relate to the following priority claim(s):
6. A copy of this notification has been sent to the receiving Office and
 - ☒ to the International Searching Authority (where the international search report has not yet been issued).
 - ☒ the designated Offices (which have already been notified of the receipt of the record copy).

The International Bureau of WIPO 34, chemin des Colombettes 1211 Geneva 20, Switzerland Facsimile No. (41-22) 740.14.35	Authorized officer <p style="text-align: center;">Aino Metcalfe</p> Telephone No. (41-22) 338.83.38
--	--

PCT

INTERNATIONAL PRELIMINARY EXAMINATION REPORT

(PCT Article 36 and Rule 70)

REC'D 05 FEB 2002

WIPO PCT

Applicant's or agent's file reference N.80650 CMK		FOR FURTHER ACTION See Notification of Transmittal of International Preliminary Examination Report (Form PCT/IPEA/416)
International application No. PCT/EP00/09708	International filing date (day/month/year) 04/10/2000	Priority date (day/month/year) 05/10/1999
International Patent Classification (IPC) or national classification and IPC A61K31/137		
Applicant COLUMBIA LABORATORIES (BERMUDA) LIMITED et al.		



1. This international preliminary examination report has been prepared by this International Preliminary Examining Authority and is transmitted to the applicant according to Article 36.
2. This REPORT consists of a total of 7 sheets, including this cover sheet.

☒ This report is also accompanied by ANNEXES, i.e. sheets of the description, claims and/or drawings which have been amended and are the basis for this report and/or sheets containing rectifications made before this Authority (see Rule 70.16 and Section 607 of the Administrative Instructions under the PCT).

These annexes consist of a total of 2 sheets.

3. This report contains indications relating to the following items:

- I ☒ Basis of the report
- II ☐ Priority
- III ☒ Non-establishment of opinion with regard to novelty, inventive step and industrial applicability
- IV ☐ Lack of unity of invention
- V ☒ Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement
- VI ☐ Certain documents cited
- VII ☐ Certain defects in the international application
- VIII ☐ Certain observations on the international application

Date of submission of the demand 12/04/2001	Date of completion of this report 01.02.2002
Name and mailing address of the international preliminary examining authority:  European Patent Office D-80298 Munich Tel. +49 89 2399 - 0 Tx: 523656 epmu d Fax: +49 89 2399 - 4465	Authorized officer Vandenbogaerde, A Telephone No. +49 89 2399 7874 

**INTERNATIONAL PRELIMINARY
EXAMINATION REPORT**

International application No. PCT/EP00/09708

I. Basis of the report

1. With regard to the **elements** of the international application (*Replacement sheets which have been furnished to the receiving Office in response to an invitation under Article 14 are referred to in this report as "originally filed" and are not annexed to this report since they do not contain amendments (Rules 70.16 and 70.17)*):

Description, pages:

1-19 as originally filed

Claims, No.:

1-22 as originally filed

23-35 as received on 27/11/2001 with letter of 23/11/2001

2. With regard to the **language**, all the elements marked above were available or furnished to this Authority in the language in which the international application was filed, unless otherwise indicated under this item.

These elements were available or furnished to this Authority in the following language: , which is:

- ☐ the language of a translation furnished for the purposes of the international search (under Rule 23.1(b)).
- ☐ the language of publication of the international application (under Rule 48.3(b)).
- ☐ the language of a translation furnished for the purposes of international preliminary examination (under Rule 55.2 and/or 55.3).

3. With regard to any **nucleotide and/or amino acid sequence** disclosed in the international application, the international preliminary examination was carried out on the basis of the sequence listing:

- ☐ contained in the international application in written form.
- ☐ filed together with the international application in computer readable form.
- ☐ furnished subsequently to this Authority in written form.
- ☐ furnished subsequently to this Authority in computer readable form.
- ☐ The statement that the subsequently furnished written sequence listing does not go beyond the disclosure in the international application as filed has been furnished.
- ☐ The statement that the information recorded in computer readable form is identical to the written sequence listing has been furnished.

4. The amendments have resulted in the cancellation of:

- ☐ the description, pages:
- ☐ the claims, Nos.:
- ☐ the drawings, sheets:

**INTERNATIONAL PRELIMINARY
EXAMINATION REPORT**

International application No. PCT/EP00/09708

5. ☐ This report has been established as if (some of) the amendments had not been made, since they have been considered to go beyond the disclosure as filed (Rule 70.2(c)):

(Any replacement sheet containing such amendments must be referred to under item 1 and annexed to this report.)

6. Additional observations, if necessary:

III. Non-establishment of opinion with regard to novelty, inventive step and industrial applicability

1. The questions whether the claimed invention appears to be novel, to involve an inventive step (to be non-obvious), or to be industrially applicable have not been examined in respect of:

☐ the entire international application.

☒ claims Nos. 13-22.

because:

☐ the said international application, or the said claims Nos. relate to the following subject matter which does not require an international preliminary examination (*specify*):

☐ the description, claims or drawings (*indicate particular elements below*) or said claims Nos. are so unclear that no meaningful opinion could be formed (*specify*):

☐ the claims, or said claims Nos. are so inadequately supported by the description that no meaningful opinion could be formed.

☒ no international search report has been established for the said claims Nos. 13-22.

2. A meaningful international preliminary examination cannot be carried out due to the failure of the nucleotide and/or amino acid sequence listing to comply with the standard provided for in Annex C of the Administrative Instructions:

☐ the written form has not been furnished or does not comply with the standard.

☐ the computer readable form has not been furnished or does not comply with the standard.

V. Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement

1. Statement

Novelty (N)	Yes:	Claims	23-35
	No:	Claims	1-12
Inventive step (IS)	Yes:	Claims	23

**INTERNATIONAL PRELIMINARY
EXAMINATION REPORT**

International application No. **PCT/EP00/09708**

	No:	Claims	1-12, 24-35
Industrial applicability (IA)	Yes:	Claims	1-12, 23-35
	No:	Claims	

2. Citations and explanations
see separate sheet

**INTERNATIONAL PRELIMINARY
EXAMINATION REPORT - SEPARATE SHEET**

International application No. PCT/EP00/09708

Re Item III

Non-establishment of opinion with regard to novelty, inventive step and industrial applicability

No international preliminary examination will be carried out in respect to the subject-matter of claims 13 to 22, which is not covered by the search report (Rule 66.1(e) PCT). However, the scope of claims 13 to 22 can be considered as identical to the subject-matter of claims 23 to 35.

Re Item V

Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement

Reference is made to the following documents:

- D1: WO 99 13862 A (COLUMBIA LABORATORIES, INC.) 25 March 1999 (1999- 03-25) cited in the application
- D2: DATABASE BIOSIS [Online] BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; 1991 LANG E K: 'organic vs. functional obstruction of the fallopian tubes differentiation with prostaglandin antagonist-mediated and beta-2-agonist-mediated hysterosalpingography and selective ostial salpingography' Database accession no. prev199192058871 XP002168612 & AJR (AMERICAN JOURNAL OF ROENTGENOLOGY), vol. 157, no. 1, 1991, pages 77-80.

- D1 describes a pharmaceutical composition comprising a beta-adrenergic agonist like terbutaline and a bioadhesive carrier like polycarbophil effective in dysmenorrhea or premature labour, after local administration in order to avoid adverse side-effects.
- D2 discloses the efficacy of the beta-adrenergic agonist terbutaline in patients with infertility disorders.

V.1 Claims 1 to 12: Novelty

The subject-matter of claims 1 to 12 is not novel in the sense of Article 33(2)

PCT over the teaching of prior art document D1. A pharmaceutical composition identical to the present claims and its therapeutic application, i.e. dysmenorrhea or premature labour, have already been disclosed in D1 (page 12 Table 1). Moreover, document D2 is also depriving the subject-matter of claim 6 from novelty.

V.2 Claims 23 to 35: Novelty - Inventive step

V.2.1 The subject-matter of independent claim 23 is new in the sense of Article 33(2) PCT over the teaching of the prior art documents. The said claim seeks protection for a new medical indication of a known pharmaceutical composition, i.e. endometriosis.

The subject-matter of claim 23 can be considered as involving an inventive step in the sense of Article 33(3) PCT for the following reasoning. Document D1, which is considered to represent the most relevant state of the art, discloses a pharmaceutical composition comprising a beta-adrenergic agonist like terbutaline and a bioadhesive carrier like polycarbophil effective in dysmenorrhea or premature labour after local administration in order to avoid adverse side-effects. The subject-matter of claim 23 differs from document D1 in that a different medical indication is claimed, i.e. endometriosis. The problem to be solved by the present invention may therefore be regarded as the provision of a further therapeutic application for a known pharmaceutical composition. Although untreated dysmenorrhea may play a role in the genesis of endometriosis (cf. D1: page 2 line 14-25), the two disorders are not always associated. Moreover, dysmenorrhea and endometriosis are treated in a different way, i.e. pain management versus hormone therapy or surgery. Therefore, it would not be obvious to a skilled person to come to the solution proposed in the present invention. Therefore, the solution proposed in claim 23 of the present application can be considered as involving an inventive step.

V.2.2 The subject-matter of independent claims 24 and 25 is novel in the sense of Article 33(2) PCT. However, claims 24 and 25 cannot be considered as involving an inventive step in the sense of Article 33(3) PCT for the following reasoning. Document D2, which is considered to represent the most relevant state of the art, discloses a pharmaceutical composition comprising the beta-adrenergic agonist terbutaline effective in infertility disorders. The subject-matter of claims 24 and 25

differs from document D2 in that the composition further comprises a bioadhesive carrier. The problem to be solved by the present invention may therefore be regarded as the provision of composition having a *superior* effect in infertility disorders. A composition comprising a beta-adrenergic agonist like terbutaline and a bioadhesive carrier like polycarbophil has already been disclosed in document D1. The said composition is used for the same purpose as described in the present application, namely local administration to the vaginal mucosa in order to have a controlled and prolonged release and less side-effects due to lower blood levels. Therefore, it would be obvious to a skilled person to select this combination and come to the solution proposed in the present invention. Therefore, the solution proposed in claims 24 and 25 of the present application cannot be considered as involving an inventive step. Dependent claims 26 to 35 do not contain any features which, in combination with the features of any claim to which they refer, meet the requirements of the PCT in respect of inventive step for the same reasoning as stated above for claims 24 and 25.

V.3 Claims 1 to 12 and claims 23 to 35 - Industrial applicability

For the assessment of the present claims 1 to 12 and claims 23 to 35 on the question whether they are industrially applicable, no unified criteria exist in the PCT Contracting States. The patentability can also be dependent upon the formulation of the claims. The EPO, for example, does not recognise as industrially applicable the subject-matter of claims to the use of a compound in medical treatment, but may allow, however, claims to a known compound for first use in medical treatment and the use of such a compound for the manufacture of a medicament for a new medical treatment.

PATENT COOPERATION TREATY

PCT

INTERNATIONAL SEARCH REPORT

(PCT Article 18 and Rules 43 and 44)

Applicant's or agent's file reference N.80650 CMK	FOR FURTHER ACTION see Notification of Transmittal of International Search Report (Form PCT/ISA/220) as well as, where applicable, item 5 below.	
International application No. PCT/EP 00/ 09708	International filing date (day/month/year) 04/10/2000	(Earliest) Priority Date (day/month/year) 05/10/1999
Applicant COLUMBIA LABORATORIES (BERMUDA) LIMITED et al.		

This International Search Report has been prepared by this International Searching Authority and is transmitted to the applicant according to Article 18. A copy is being transmitted to the International Bureau.

This International Search Report consists of a total of 4 sheets.

☒ It is also accompanied by a copy of each prior art document cited in this report.

1. Basis of the report

a. With regard to the **language**, the international search was carried out on the basis of the international application in the language in which it was filed, unless otherwise indicated under this item.

☐ the international search was carried out on the basis of a translation of the international application furnished to this Authority (Rule 23.1(b)).

b. With regard to any **nucleotide and/or amino acid sequence** disclosed in the international application, the international search was carried out on the basis of the sequence listing :

☐ contained in the international application in written form.

☐ filed together with the international application in computer readable form.

☐ furnished subsequently to this Authority in written form.

☐ furnished subsequently to this Authority in computer readable form.

☐ the statement that the subsequently furnished written sequence listing does not go beyond the disclosure in the international application as filed has been furnished.

☐ the statement that the information recorded in computer readable form is identical to the written sequence listing has been furnished

2. ☒ **Certain claims were found unsearchable** (See Box I).

3. ☐ **Unity of invention is lacking** (see Box II).

4. With regard to the **title**,

☒ the text is approved as submitted by the applicant.

☐ the text has been established by this Authority to read as follows:

5. With regard to the **abstract**,

☒ the text is approved as submitted by the applicant.

☐ the text has been established, according to Rule 38.2(b), by this Authority as it appears in Box III. The applicant may, within one month from the date of mailing of this international search report, submit comments to this Authority.

6. The figure of the **drawings** to be published with the abstract is Figure No.

☐ as suggested by the applicant.

☐ because the applicant failed to suggest a figure.

☐ because this figure better characterizes the invention.

☐ None of the figures.

INTERNATIONAL SEARCH REPORT

International Application No
PCT/EP 00/09708

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 A61K31/137 A61K47/32 A61P15/02 A61P15/08 A61K31/135
A61K9/00 A61K9/20

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

BIOSIS, WPI Data, PAJ, EPO-Internal

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 99 13862 A (COLUMBIA LABORATORIES, INC.) 25 March 1999 (1999-03-25) cited in the application	1-12
Y	page 12, line 1 -page 14, line 2 claims 1-22 --- -/--	23-28



Further documents are listed in the continuation of box C.



Patent family members are listed in annex.

* Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search

31 May 2001

Date of mailing of the international search report

18/06/2001

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Benz, K

INTERNATIONAL SEARCH REPORT

International Application No

PCT/EP 00/09708

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	DATABASE BIOSIS 'Online! BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; 1991 LANG E K: "organic vs. functional obstruction of the fallopian tubes differentiation with prostaglandin antagonist-mediated and beta-2-agonist-mediated hysterosalpingography and selective ostial salpingography" Database accession no. prev199192058871 XP002168612 abstract & AJR (AMERICAN JOURNAL OF ROENTGENOLOGY), vol. 157, no. 1, 1991, pages 77-80, ---	23-28
A	WO 93 02662 A (L.C. PHARMCHEM LTD.) 18 February 1993 (1993-02-18) page 8; example 2 -----	28

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/EP 00/09708

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9913862 A	25-03-1999	US 6126959 A	03-10-2000
		AU 9131198 A	05-04-1999
		BR 9812134 A	18-07-2000
		CN 1270514 T	18-10-2000
		EP 1011632 A	28-06-2000
		NO 20001287 A	10-03-2000
		ZA 9808328 A	23-02-1999
<hr/>			
WO 9302662 A	18-02-1993	IT 1251114 B	04-05-1995
		AT 129149 T	15-11-1995
		AU 2345492 A	02-03-1993
		CA 2114216 A	18-02-1993
		DE 69205579 D	23-11-1995
		DE 69205579 T	04-04-1996
		DK 596935 T	22-01-1996
		EP 0596935 A	18-05-1994
		JP 6509348 T	20-10-1994
<hr/>			

PCT

INTERNATIONAL SEARCH REPORT

(PCT Article 18 and Rules 43 and 44)

Applicant's or agent's file reference N.80650 CMK	FOR FURTHER ACTION see Notification of Transmittal of International Search Report (Form PCT/ISA/220) as well as, where applicable, item 5 below.	
International application No. PCT/EP 00/09708	International filing date (day/month/year) 04/10/2000	(Earliest) Priority Date (day/month/year) 05/10/1999
Applicant COLUMBIA LABORATORIES (BERMUDA) LIMITED et al.		

This International Search Report has been prepared by this International Searching Authority and is transmitted to the applicant according to Article 18. A copy is being transmitted to the International Bureau.

This International Search Report consists of a total of 4 sheets.



It is also accompanied by a copy of each prior art document cited in this report.

1. Basis of the report

- a. With regard to the **language**, the international search was carried out on the basis of the international application in the language in which it was filed, unless otherwise indicated under this item.



the international search was carried out on the basis of a translation of the international application furnished to this Authority (Rule 23.1(b)).

- b. With regard to any **nucleotide and/or amino acid sequence** disclosed in the international application, the international search was carried out on the basis of the sequence listing :



contained in the international application in written form.



filed together with the international application in computer readable form.



furnished subsequently to this Authority in written form.



furnished subsequently to this Authority in computer readable form.



the statement that the subsequently furnished written sequence listing does not go beyond the disclosure in the international application as filed has been furnished.



the statement that the information recorded in computer readable form is identical to the written sequence listing has been furnished

2. ☒ **Certain claims were found unsearchable** (See Box I).

3. ☐ **Unity of invention is lacking** (see Box II).

4. With regard to the **title**,



the text is approved as submitted by the applicant.



the text has been established by this Authority to read as follows:

5. With regard to the **abstract**,



the text is approved as submitted by the applicant.



the text has been established, according to Rule 38.2(b), by this Authority as it appears in Box III. The applicant may, within one month from the date of mailing of this international search report, submit comments to this Authority.

6. The figure of the **drawings** to be published with the abstract is Figure No.




as suggested by the applicant.



because the applicant failed to suggest a figure.



because this figure better characterizes the invention.



None of the figures.

INTERNATIONAL SEARCH REPORT

International Application No

PC: EP 00/09708

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 A61K31/137 A61K47/32 A61P15/02 A61P15/08 A61K31/135
A61K9/00 A61K9/20

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

BIOSIS, WPI Data, PAJ, EPO-Internal

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 99 13862 A (COLUMBIA LABORATORIES, INC.) 25 March 1999 (1999-03-25) cited in the application	1-12
Y	page 12, line 1 - page 14, line 2 claims 1-22 --- -/--	23-28

☒ Further documents are listed in the continuation of box C.☒ Patent family members are listed in annex.

* Special categories of cited documents:

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- *&* document member of the same patent family

Date of the actual completion of the international search

31 May 2001

Date of mailing of the international search report

18/06/2001

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Benz, K

INTERNATIONAL SEARCH REPORT

International Application No
PCT/EP 00/09708

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	DATABASE BIOSIS 'Online! BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; 1991 LANG E K: "organic vs. functional obstruction of the fallopian tubes differentiation with prostaglandin antagonist-mediated and beta-2-agonist-mediated hysterosalpingography and selective ostial salpingography" Database accession no. prev199192058871 XP002168612 abstract & AJR (AMERICAN JOURNAL OF ROENTGENOLOGY), vol. 157, no. 1, 1991, pages 77-80, ---	23-28
A	WO 93 02662 A (L.C. PHARMCHEM LTD.) 18 February 1993 (1993-02-18) page 8; example 2 -----	28

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/EP 00/09708

Patent document cited in search report		Publication date	Patent family member(s)		Publication date
WO 9913862	A	25-03-1999	US	6126959 A	03-10-2000
			AU	9131198 A	05-04-1999
			BR	9812134 A	18-07-2000
			CN	1270514 T	18-10-2000
			EP	1011632 A	28-06-2000
			NO	20001287 A	10-03-2000
			ZA	9808328 A	23-02-1999
WO 9302662	A	18-02-1993	IT	1251114 B	04-05-1995
			AT	129149 T	15-11-1995
			AU	2345492 A	02-03-1993
			CA	2114216 A	18-02-1993
			DE	69205579 D	23-11-1995
			DE	69205579 T	04-04-1996
			DK	596935 T	22-01-1996
			EP	0596935 A	18-05-1994
			JP	6509348 T	20-10-1994

INTERNATIONAL SEARCH REPORT

Inter: 1st Application No

PCT/EP 00/09708

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 A61K31/137 A61K47/32 A61P15/02 A61P15/08 A61K31/135
A61K9/00 A61K9/20

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

BIOSIS, WPI Data, PAJ, EPO-Internal

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 99 13862 A (COLUMBIA LABORATORIES, INC.) 25 March 1999 (1999-03-25) cited in the application page 12, line 1 -page 14, line 2	1-12
Y	claims 1-22 --- -/--	23-28



Further documents are listed in the continuation of box C.



Patent family members are listed in annex.

* Special categories of cited documents:

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- *&* document member of the same patent family

Date of the actual completion of the international search

31 May 2001

Date of mailing of the international search report

18/06/2001

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Benz, K

INTERNATIONAL SEARCH REPORT

International Application No

PCT/EP 00/09708

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	<p>DATABASE BIOSIS 'Online! BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; 1991 LANG E K: "organic vs. functional obstruction of the fallopian tubes differentiation with prostaglandin antagonist-mediated and beta-2-agonist-mediated hysterosalpingography and selective ostial salpingography" Database accession no. prev199192058871 XP002168612 abstract & AJR (AMERICAN JOURNAL OF ROENTGENOLOGY), vol. 157, no. 1, 1991, pages 77-80,</p>	23-28
A	<p>WO 93 02662 A (L.C. PHARMCHEM LTD.) 18 February 1993 (1993-02-18) page 8; example 2</p>	28

INTERNATIONAL SEARCH REPORT

information on patent family members

International Application No

PCT/EP 00/09708

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
W0 9913862 A	25-03-1999	US 6126959 A	03-10-2000
		AU 9131198 A	05-04-1999
		BR 9812134 A	18-07-2000
		CN 1270514 T	18-10-2000
		EP 1011632 A	28-06-2000
		NO 20001287 A	10-03-2000
		ZA 9808328 A	23-02-1999
W0 9302662 A	18-02-1993	IT 1251114 B	04-05-1995
		AT 129149 T	15-11-1995
		AU 2345492 A	02-03-1993
		CA 2114216 A	18-02-1993
		DE 69205579 D	23-11-1995
		DE 69205579 T	04-04-1996
		DK 596935 T	22-01-1996
		EP 0596935 A	18-05-1994
		JP 6509348 T	20-10-1994